NewsEvents

Your Yourlocation: Home > The treatment of tiotropium bromide(136310-93-5) is modified in the guidelines

For patients with proper use of inhalers, good compliance, use of Level 4 therapy and other viable asthma control regimens, but still persistent asthma symptoms or asthma exacerbations should be considered for patients with experience in intensive asthma treatment D-level evidence. In the treatment regimen, the expression of "tiotropium bromide(136310-93-5) in the treatment of adolescents with acute onset history (≥ 12 years)" was added by the soft mist inhaler.

Specifically, the 2015 edition of "tiotropium bromide: can be used for the fourth level after treatment is still acute asthma attacks in patients with acute mist inhalation can be used as an additional treatment. Tiotropium can improve the use of lung function, delay the onset of acute episodes (Level B), but not for children <18 years of age.

TABB can be used in patients with acute exacerbation of asthma after treatment at level 4. Tiotropium bromide(136310-93-5) (administered by a soft mist inhaler) can improve lung function in patients with severe delay acute attack time (level B evidence)."

2016 version of the guidelines in the treatment program, also added the "mepolizumab (mepolizumab) for the treatment of severe eosinophil asthma (≥ 12 years old)."

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved